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Background: Tiotropium bromide is an effective therapy for COPD patients. Comparing across programs
tiotropium RespimatW Soft Mist™ inhaler was at least as efficacious as tiotropium HandiHalerW, however, concerns
have been raised about tiotropium’s safety when given via RespimatW.
Methods: The TIOSPIRW trial (NCT01126437) compares the safety and efficacy of tiotropium RespimatW 5 μg once
daily (marketed) and 2.5 μg once daily (investigational) with tiotropium HandiHalerW 18 μ once daily (marketed).
The hypotheses to be tested are 1). that tiotropium RespimatW 5 μg once daily and RespimatW 2.5 μg once daily
are non-inferior to HandiHalerW in terms of all-cause mortality, and 2). that tiotropium RespimatW 5 μg once daily is
superior to HandiHalerW in terms of time to first exacerbation. A spirometry substudy evaluates the bronchodilator
efficacy. The trial is a randomized, double-blind, double dummy, event-driven, parallel group study. Participants can
use any background treatment for COPD except inhaled anticholinergic agents. The study encompasses a wide
range of COPD patients, e.g. patients with stable cardiac diseases including arrhythmia can be included. Clinical
sites are international and include both primary care as well as specialists.
Results: To date, over 17,000 participants have been randomized from over 1200 sites in 50 countries with an
anticipated treatment duration of 2–3 years.
Conclusion: TIOSPIRW will provide precise estimates of the relative safety and efficacy of the RespimatW and
HandiHalerW formulations of tiotropium, assess potential dose-dependence of important outcomes and provide
information on the clinical epidemiology of COPD in a large international patient cohort.
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Tiotropium is a long-acting antimuscarinic bronchodilator
indicated for maintenance bronchodilation in patients with
chronic obstructive pulmonary disease (COPD) for once-
daily inhalation treatment. Two formulations of tiotropium
have been developed: SPIRIVAW HandiHalerW 18 μg once
daily, a dry powder inhaler (DPI), received initial approval
in 2002, and is now approved in more than 100 countries.* Correspondence: rwise@jhmi.edu
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reproduction in any medium, provided the orSPIRIVAW RespimatW 5 μg once daily Soft Mist™ Inhaler
(SMI) was developed as a novel multi-dose aqueous aero-
sol delivery device. It is approved in more than 85 coun-
tries, with initial approval received in 2007 [1].
Tiotropium HandiHalerW 18 μg and RespimatW 5 μg
have been developed in separate stand-alone programs.
Until now, they have only been directly compared in trials
up to 4-week duration. Clinical trials with tiotropium
HandiHalerW 18 μg and RespimatW 5 μg once daily have
demonstrated similar clinically important improvements
in lung function, symptoms, and health-related quality of
life. In a prespecified pooled analysis of two 4-week,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tiotropium RespimatW and tiotropium HandiHalerW 18 μg
were both significantly superior to placebo on the primary
endpoint of trough forced expiratory volume in 1 second
(FEV1) response. Tiotropium Respimat
W 5 μg was non-
inferior to tiotropium HandiHalerW in terms of broncho-
dilator efficacy and both formulations provided a similar
systemic availability [2]. In a 4-week crossover study of
134 Japanese patients with COPD [3] tiotropium
RespimatW 5 μg and tiotropium HandiHalerW 18 μg
had similar lung function efficacy, safety, and pharma-
cokinetic (PK) profiles [3]. Taken together, these find-
ings indicate that tiotropium RespimatW 5 μg and
tiotropium HandiHalerW 18 μg have similar efficacy,
systemic exposure, and safety.
Exacerbation benefits have been observed in both clin-
ical trial programs. In the 1-year trial with tiotropium
RespimatW 5 μg, [4] the hazard ratio (HR) for time to
COPD exacerbation (tiotropium/placebo) was 0.69 (95%
confidence interval [CI]: 0.63–0.77). Comparable results
using the largest tiotropium HandiHalerW trial, Under-
standing Potential Long-term Impacts on Function with
Tiotropium (UPLIFTW) demonstrated an HR of 0.86
(95% CI, 0.81–0.91) after 4 years [5]. Cross-study com-
parisons therefore suggest potentially superior effects on
reducing the risk of an exacerbation with the RespimatW
formulation; however, there have not been direct com-
parisons in clinical trials of sufficient size and duration
to determine whether there are true differences in ex-
acerbation outcomes.
Mortality has been evaluated in HandiHalerW and
RespimatW trials [6,7]. Intention-to-treat mortality has
been analyzed for the largest study with HandiHalerW
formulation (4 years, 5992 patients in UPLIFTW) [5], for
the three, 1-year studies with the RespimatW formula-
tion, and in a further 6-month study [4,8,9]. In the
UPLIFTW study the risk of a fatal event was lower with
tiotropium treatment (in the HandiHalerW formulation)
than with placebo. For the 4-year, protocol-defined study
period up to day 1440, among patients for whom vital-
status information was available, 921 patients died:
14.4% in the tiotropium group and 16.3% in the placebo
group (hazard ratio, 0.87; 95% CI, 0.76 - 0.99) [5]. In a
retrospective, pooled analysis of the three 1-year and
one 6-month placebo-controlled trials with tiotropium
RespimatW, including 6096 patients, a numeric increase
in all-cause mortality was seen in patients treated with
tiotropium RespimatW 5 μg (68; incidence rate [IR]: 2.64
cases per 100 patient-years) compared with placebo (51;
IR: 1.98) showing a rate ratio of 1.33 (95% CI: 0.93–1.92)
for the planned treatment period; the excess in mortality
was observed in patients with known rhythm disorders
[1]. The causes of death were diverse and a causal rela-
tionship between the use of tiotropium RespimatW andmortality has not been established. In contrast to pooled
analyses on trial-level data of three of these studies, in-
cluding the 10 μg non-marketed dose, [7,10,11] the
pooled analyses based on patient-level data have shown
a numeric, but non-statistically significant increase in
all-cause mortality [6,9]. The Cochrane Review meta-
analysis, thus concluded: “Head-to-head trials comparing
the dry powder HandiHalerW to the soft mist RespimatW
inhaler are required before firm conclusions can be
drawn concerning the difference in mortality rates be-
tween the inhalers” [11].
Direct comparison studies of tiotropium HandiHalerW
18 μg with RespimatW 5 μg have been limited to 4-week
crossover studies on PK and lung function parameters
mentioned above. Therefore, prospective data from a trial
of adequate size and duration is the appropriate way to es-
tablish whether tiotropium RespimatW 5 μg has compar-
able safety and efficacy with tiotropium HandiHalerW
including rare events, i.e. events of death or exacerbations
outcomes. A treatment arm with tiotropium RespimatW
2.5 μg is also included because this dose may be preferred
in combination with a long-acting beta-agonist (on-
going clinical development program of a fixed-dose
combination).
A recent comprehensive review of meta-analyses and
pharmaco-epidemiologic studies have also raised the
possibility that mortality is increased by tiotropium de-
livered by RespimatW [12]. Although it has been theo-
rized that there may be greater system absorption, PK
and pharmacodynamic studies have shown similar pro-
files for the two currently marketed formulations of
tiotropium [2,3]. A recent high-resolution PK study has
shown a slightly lower peak serum concentration with
RespimatW [13]. Thus, at present, there is no clear
mechanistic explanation for an increased risk profile for
tiotropium RespimatW compared with HandiHalerW. Be-
cause of this unresolved controversy, there is a compel-
ling need to conduct a mortality-endpoint driven trial
comparing the two inhaler formulations.
The purpose of this manuscript is to describe the ration-
ale and methods for TIOtropium Safety and Performance
In RespimatW (TIOSPIRW) trial (NCT01126437), a multi-
national, double-blind, comparative trial evaluating the
safety and efficacy of two doses of tiotropium RespimatW
(once-daily 2.5 or 5 μg), with tiotropium HandiHalerW
(once-daily 18 μg). The trial is a large-scale, event-driven,
non-inferiority trial with two primary endpoints: time to




The first primary endpoint for TIOSPIRW is all-cause
mortality. Clinical sites follow all randomized patients
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who prematurely discontinued study medication, and
collect medical information regarding the date and cause
of fatal events.
The second primary endpoint for TIOSPIRW is time to
first COPD exacerbation. COPD exacerbations are de-
fined as a complex of two or more respiratory symptoms
(worsening dyspnea, cough, sputum production, chest
tightness, or wheezing) related to the underlying COPD,
with duration of 3 days or more, that require a change
in treatment. Treatment changes include acute treat-
ment with antibiotics and/or steroids, or an addition of
new maintenance bronchodilator. Mild exacerbations are
those that require new prescription of bronchodilator only,
moderate exacerbations are those that require antibiotics
and/or systemic corticosteroids without hospitalization, and
severe exacerbations are those that lead to hospitalization.
The onset date of exacerbations is defined by the onset of
the first recorded symptom. Exacerbations that occur within
7 days of onset of a prior exacerbation are counted as a sin-
gle exacerbation.
Secondary outcome measures will also be analyzed by
treatment group to support inferences derived from the
primary analysis. These measures include the number of
COPD exacerbations, the time to first exacerbation asso-
ciated with hospitalization, the number of exacerbations
associated with hospitalization, and the time to the first
major adverse cardiovascular event (e.g. fatal event in
system organ classes cardiac and vascular disorders,
myocardial infarction [MI], or stroke). Criteria for defin-
ition of major adverse cardiovascular events are specified
in the protocol and are adjudicated by the site investigator
who is masked to the study treatment (see Appendix). In
a subset of approximately 1300 patients, spirometry was
conducted at baseline and is repeated every 24 weeks. Pa-
tients in the substudy perform pulmonary function tests
at a single time point in triplicate to record trough FEV1
and forced vital capacity (FVC). Tertiary analyses of treat-
ment groups will be performed on subgroups specified byFigure 1 TIOSPIRW study design. R, randomization; C, Close of study onc
For patients who discontinue trial medication before the planned end of thdemographic variables, co-morbid conditions, disease se-
verity, and concomitant medications.Treatment arms
The study consists of three parallel treatment arms:
tiotropium 18 μg once daily via HandiHalerW, tiotropium
5 μg once daily (2.5 μg × two inhalations) via RespimatW,
and tiotropium 2.5 μg once daily (1.25 μg × two inhala-
tions) via RespimatW (Figure 1). Each participant was pro-
vided with two inhalers, RespimatW and HandiHalerW, one
of which contained active medication and the other
contained placebo (double dummy). All patients will be
followed up for vital status until the end of the study, even
if treatment is discontinued prematurely. The planned
treatment time for patients will be between 2 and 3 years
and is dependent on the number of fatal events observed
with study completion expected in 2013. At each 12-week
visit, inhalers are collected and new inhalers are distrib-
uted. Adherence with drug treatment is ascertained by
counting unused HandiHalerW capsules and recording the
remaining doses on the RespimatW dose-counter. Proper
use of the inhalers is ascertained by direct observation at
the first study visit and is maintained by counseling and
demonstration, if needed, at subsequent study visits.
The eligibility screening visit may be the same day as
the enrollment visit unless it is necessary to acquire off-
site source documents. Participants are randomly assigned
to one of the three treatment arms with equal probability
using an interactive voice or web response system. Each
patient is allocated a treatment box containing a unique
medication number. The randomization schema is strati-
fied by clinical center using a permuted block design with
concealment of subsequent allocation.Concomitant medication
All classes of maintenance respiratory medications and
medications for other diseases including cardiac diseases
and arrhythmia are permitted throughout this trial. Onlye the planned 1266 events have been reached; SMI, Soft Mist™ Inhaler.
e trial, vital status follow-up continues every 12 weeks.
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gics) need to be discontinued.Participant selection
Inclusion criteria
The eligibility criteria are similar to those in previous late
development or post-approval tiotropium HandiHalerW
and RespimatW clinical trials [5]. Inclusion criteria are:
men or women aged 40 years or older with at least 10
pack-years of smoking, a clinical diagnosis of COPD,
post-bronchodilator spirometry showing a FEV1/FVC
ratio ≤0.70, and a FEV1 ≤70% of predicted. Except for
those included in the pulmonary function substudy,
pre- and post- bronchodilator spirometry performed
within 6 months of enrollment could be acquired from
patient records. Participants must also demonstrate
ability to use both the HandiHalerW and RespimatW
devices.Exclusion criteria
Exclusion criteria were rather liberal to reflect a typical
COPD population: Participants were excluded if they
have significant diseases other than COPD that put the
patient at risk for participation in the study or that
might interfere with participation in the study. Patients
with concomitant cardiac disease could be included
unless they had: MI within 6 months, hospitalization for
heart failure within 12 months, and unstable or life-
threatening arrhythmia requiring intervention or change
in drug therapy within 12 months. Patients were also
excluded if they had other significant lung diseases,
such as active tuberculosis, asthma, cystic fibrosis, clinic-
ally evident bronchiectasis, interstitial lung disease,
resectional lung surgery, or pulmonary thromboembol-
ism. Patients with cancer (other than skin basal cell)
requiring therapy within 5 years, drug or alcohol abuse
within 12 months, known hypersensitivity to tiotropium,
narrow-angle glaucoma, symptomatic bladder-neck ob-
struction, pregnancy, lactation, or child-bearing potential
not on contraceptives were excluded. Patients were not
excluded for radiographic evidence of bronchiectasis if
they were not being treated for this condition. Partici-
pants with unstable COPD evidenced by an exacerbation
within 4 weeks, plans for lung transplantation or lung
volume reduction surgery, use of oxygen for more than
12 hours/day, completion of a pulmonary rehabilitation
program within 6 weeks of screening, or an unstable
dose of systemic corticosteroid medication or chronic
use of corticosteroid medication more than the equiva-
lent of 10 mg per day of prednisone were excluded. Par-
ticipants were also not permitted to participate in other
intervention trials or have used an investigational drug
within 30 days of enrollment.Study organization and oversight
The scientific oversight of the trial is provided by a Sci-
entific Steering Committee (SSC), which is responsible
for making recommendations to the sponsor regarding
study design, execution, interpretation, and publication
of results. The SSC meets every 6 months to review both
the progress and blinded study data. A separate and in-
dependent Data Monitoring Committee (DMC) reviews
listings and tabulations of adverse events and deaths by
treatment group (unblinded if requested) and makes
recommendations to the sponsor about continuation of
the trial or modifications that are necessary to protect
the safety of the participants. The DMC meets every
4 months or more frequently as needed. A Mortality
Adjudication Committee (MAC), masked to treatment
assignment, is charged with reviewing medical docu-
mentation, case report forms, and witness accounts for
all deaths in order to establish an attributable cause
of death.
The protocol was approved by the respective institu-
tional review boards. The trial is conducted in compli-
ance with the protocol, the principles laid down in the
Declaration of Helsinki, in accordance with the ICH
Harmonised Tripartite Guideline for Good Clinical Prac-
tice (GCP) and in accordance with applicable regulatory
requirements. All patients provided written informed
consent prior to participation.
Statistical design
The event-driven trial is designed to end when approxi-
mately 1266 deaths are reported. Based on expected
mortality, the duration of the trial was estimated to be
3.5 years with 1.5 years enrollment period. The primary
mortality analysis is to be conducted using all patients
who were assigned treatment and took at least one dose
of study drug, regardless of subsequent premature dis-
continuation of trial. Patients lost to follow-up are cen-
sored at the time of last known vital status. For the
primary exacerbation analysis, patients are censored at
the time of study medication discontinuation.
Mortality is the primary design variable that dictates
sample size. The primary analysis includes both mortal-
ity and time to first COPD exacerbation, evaluated with
the Cox proportional hazard model (with no covariate
adjustment) using a hierarchical analysis scheme. This
scheme requires that each null hypothesis be tested and
rejected before proceeding to the next hypothesis to pre-
serve the trial type I statistical error. The comparisons
are to be tested in the following order compared with
the HandiHalerW treatment group: 1) non-inferiority for
time to death for RespimatW 5 μg; 2) non-inferiority for
time to death for RespimatW 2.5 μg; 3) superiority for time
to first COPD exacerbation for 5 μg RespimatW. The mar-
gin of non-inferiority is set at 1.25 (HR) based on practical
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the HR between RespimatW and HandiHalerW lies below
1.25, the null hypothesis is rejected.
Sample size and power
Assuming a one-sided p-value of 0.025, power of 90%
and a non-inferiority margin of 1.25, the total number of
events is estimated to be 1266 for the three groups. As-
suming a 1.5-year accrual and a maximum follow-up of
3.5 years with 99% ascertainment of vital status, and a
5.6% rate of mortality at 2 years, a total of 16,800 partici-
pants (5600 per treatment group) are required.
With this sample size, assuming a two-sided p-value of
5%, and a 35% treatment discontinuation rate with 60%
exacerbation rate in the HandiHalerW group, the trial is
able to detect an 8% reduction in the HR for first exacer-
bation with 90% power.
Results
Study progress
To train site investigators and staff, a total of 17 training
meetings were conducted over a 6-month period at the
initiation of the trial.
A total of 17,182 participants were randomized to
treatment in more than 1200 investigator sites in 50
countries. Of these, 17,135 participants (99.7%) received
at least one dose of medication, constituting the study
population.
The trial was initiated in May 2010; enrollment was
faster than expected and was completed in April 2011.
Because of the quick enrollment, it is likely that the trial
duration may be closer to 3 years than the originally
expected 3.5 years. Final data collection for the primary
outcome measure is anticipated in 2013.
Discussion
The TIOSPIRW trial has several unique characteristics
and presents challenges for the investigators. This is one
of the largest COPD trials ever performed, and is being
conducted on an international scope. The large size of
the trial is dictated by two factors. First is the size of the
study population required to assess mortality as an out-
come measure, which is an uncommon event in ambula-
tory patients with COPD who are not oxygen-dependent
[14]. Second, the primary outcome analysis is being
conducted with a non-inferiority design comparing only
active treatments. Thus, this trial is designed to provide
a precise estimate of mortality rates as well as exacerba-
tion rates. Another unique feature of this trial is that it
compares the same active treatment tiotropium in differ-
ent marketed delivery systems, formulations and doses
to establish the impact of delivery system or dose on
clinically rare outcomes, mortality and exacerbations.This trial has many of the characteristics of a large-scale
comparative effectiveness trial: all of the patients are taking
active treatments; the inclusion criteria are broad and the
study sites are widely representative of both academic and
community practices; the outcome measures, mortality
and exacerbation rates, are clinically relevant and have im-
portant economic implications; and participants are per-
mitted to use their usual background treatments for
COPD that do not replicate the class of drug used in the
trial. Placebo is not included with the purpose of eliminat-
ing a differential drop-out bias, which can be induced by
more exacerbations, worse symptoms, and possibly re-
duced life expectancy. The absence of a placebo group may
also facilitate follow-up and drug adherence during a trial
of relatively long duration. The duration of the trial (pa-
tients are be on treatment for between 2 and 3.5 years) al-
lows for long-term data to be collected on safety and
efficacy, including spirometry in the substudy. Thus,
TIOSPIRW provides clinically useful information about the
optimal use of tiotropium in COPD and guides clinicians,
policy makers, and payers. Beyond that, the TIOSPIRW trial
can provide information as to the validity of spirometry as
a surrogate marker or predictor of efficacy in rare out-
comes such as exacerbations.
Despite the organizational and logistic challenges of
such a large trial, accrual of participants was faster than
expected. This reflected the broad inclusion criteria that
were designed to enroll patients who might be encoun-
tered in routine clinical practice. Patients with a medical
history including MI, cardiac arrhythmia, or cardiac failure
were generally included and only excluded if MI occurred
within 6 months or less, if cardiac arrhythmia was un-
stable or life threatening, requiring intervention or a
change in drug therapy during the past year, or if cardiac
failure of New York Heart Association Class III or IV led
to hospitalization during the past year. Moreover, all par-
ticipants were assigned to an active treatment arm and
were permitted to continue other background medications
that did not interfere with study participation, and could
participate in their usual care routine. One of the chal-
lenges in training the large number of investigators, many
of whom were community practitioners, was to emphasize
the statistical underpinnings of the trial, and the need for
high levels of follow up whether or not patients remained
on study drug. The study organization and oversight is
similar to that used in other large multicenter trials and is
designed to provide continuing monitoring and review of
the data integrity and patient safety at several levels. This
includes an SSC, a DMC, and a MAC that represent the
international scope of the trial.
Conclusions
In summary, the TIOSPIRW trial is designed as a large-
scale international trial to ascertain the relative safety
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tiotropium in patients with COPD, based on mortality as
the endpoint of highest relevance to clinical outcomes
and patient safety, and to concomitantly determine the
relative efficacy in preventing COPD exacerbations that
are of high relevance to clinical outcomes and cost bur-
den of COPD. This trial requires unique logistic, design,
and statistical considerations that differ from smaller tri-
als designed to measure bronchodilator efficacy. More-
over, this large cohort of COPD patients can provide
important insights into the clinical epidemiology of
COPD around the world.
Appendix
Major Adverse Cardiovascular Events include the following:
 Stroke
 Transient Ischemic Attack
 Sudden Cardiac Death
 Myocardial Infarction
Definitions of Major Adverse Cardiovascular Events
Stroke
Stroke is defined as an acute onset of focal neurological
deficit of presumed vascular origin lasting for 24 hours
or more or resulting in death. Additionally, an event
lasting <24 hours is considered as a stroke if this is due
to 1) therapeutic intervention by pharmacological or
non-pharmacological means (i.e., thrombolytics, intra-
cranial angioplasty), or 2) brain imaging available docu-
ments a new hemorrhage or infarct. The stroke is
categorized as ischemic or hemorrhagic (based on im-
aging or autopsy) or type unknown. Fatal stroke is de-
fined as death from any cause within 30 days of stroke.
Transient Ischemic Attacks (TIA)
A TIA is defined as a rapid onset of a focal neurological
deficit that resolves spontaneously without evidence of
residual symptoms at 24 hours.
Acute Myocardial Infarction
Any one of the following criteria meets the diagnosis for
myocardial infarction (MI).
1. Detection of elevated values of cardiac biomarkers
(preferably troponin T or I) above the 99th
percentile of the upper reference limit (URL)
together with evidence of myocardial ischemia with
at least one of the following:
 Ischemic symptoms;
 ECG changes indicative of new ischemia (new ST-T
changes or new left bundle branch block [LBBB]);
 Development of pathological Q waves in
the ECG; Imaging evidence of new loss of viable
myocardium or new regional wall motion
abnormality.
2. Sudden unexpected cardiac death, including cardiac
arrest, with symptoms suggestive of myocardial
ischemia, or accompanied by new ST elevation, or
new LBBB, or definite new thrombus by coronary
angiography but dying before blood samples could
be obtained, or in the lag phase of cardiac
biomarkers in the blood.
3. For percutaneous coronary intervention (PCI) in
patients with normal baseline values, elevations of
cardiac biomarkers above 99th percentile of the URL
are indicative of peri-procedural myocardial
necrosis.
4. For coronary artery bypass graft (CABG) in patients with
normal baseline values, elevations of cardiac biomarkers
above the 99th percentile of the URL are indicative of
peri-procedural myocardial necrosis. By
convention, increases of biomarkers greater than
5 × 99th percentile of the URL plus either new
pathological Q waves or new LBBB, or
angiographically documented new graft or native
coronary artery occlusion, or imaging evidence of new
loss of viable myocardium have been designated as
defining CABG-related MI.
5. Pathological findings post-mortem of an acute MI.
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